These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17315418)

  • 21. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
    Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
    Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prescribing Opioid Replacement Therapy in U.S. Correctional Settings.
    Farahmand P; Modesto-Lowe V; Chaplin MM
    J Am Acad Psychiatry Law; 2017 Dec; 45(4):472-477. PubMed ID: 29282239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rate of community methadone treatment reporting at jail reentry following a methadone increased dose quality improvement effort.
    Harris A; Selling D; Luther C; Hershberger J; Brittain J; Dickman S; Glick A; Lee JD
    Subst Abus; 2012; 33(1):70-5. PubMed ID: 22263715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initiating methadone in jail and in the community: Patient differences and implications of methadone treatment for reducing arrests.
    Schwartz RP; Kelly SM; Mitchell SG; Gryczynski J; O'Grady KE; Jaffe JH
    J Subst Abuse Treat; 2019 Feb; 97():7-13. PubMed ID: 30577902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of substitution treatment in prisons--a literature review.
    Stallwitz A; Stöver H
    Int J Drug Policy; 2007 Dec; 18(6):464-74. PubMed ID: 18061872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Evolving Medicolegal Precedent for Medications for Opioid Use Disorder in U.S. Jails and Prisons.
    Toyoshima T; McNiel DE; Schonfeld A; Binder R
    J Am Acad Psychiatry Law; 2021 Dec; 49(4):545-552. PubMed ID: 34341145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A qualitative assessment of an abstinence-oriented therapeutic community for prisoners with substance use disorders in Kyrgyzstan.
    Azbel L; Rozanova J; Michels I; Altice FL; Stöver H
    Harm Reduct J; 2017 Jul; 14(1):43. PubMed ID: 28693573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioid addiction and incarceration: an overview.
    Schwartz RP; McKenzie M; Rich JD
    Med Health R I; 2007 May; 90(5):157-8. PubMed ID: 17557660
    [No Abstract]   [Full Text] [Related]  

  • 29. Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.
    Gordon MS; Vocci FJ; Fitzgerald TT; O'Grady KE; O'Brien CP
    Contemp Clin Trials; 2017 Feb; 53():130-136. PubMed ID: 28011389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of the Chinese police in methadone maintenance therapy: a literature review.
    Meng J; Burris S
    Int J Drug Policy; 2013 Nov; 24(6):e25-34. PubMed ID: 23623719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methadone maintenance treatment may improve completion rates and delay opioid relapse for opioid dependent individuals under community corrections supervision.
    Clark CB; Hendricks PS; Lane PS; Trent L; Cropsey KL
    Addict Behav; 2014 Dec; 39(12):1736-40. PubMed ID: 25117851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with interest in receiving prison-based methadone maintenance therapy in Malaysia.
    Mukherjee TI; Wickersham JA; Desai MM; Pillai V; Kamarulzaman A; Altice FL
    Drug Alcohol Depend; 2016 Jul; 164():120-127. PubMed ID: 27207155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Barriers to retention in methadone maintenance therapy among people who inject drugs in Bangkok, Thailand: a mixed-methods study.
    Hayashi K; Ti L; Ayutthaya PPN; Suwannawong P; Kaplan K; Small W; Kerr T
    Harm Reduct J; 2017 Sep; 14(1):63. PubMed ID: 28882155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addiction Treatment Within U.S. Correctional Facilities: Bridging the Gap Between Current Practice and Evidence-Based Care.
    Wakeman SE; Rich JD
    J Addict Dis; 2015; 34(2-3):220-5. PubMed ID: 26076211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opioid substitution treatment in pretrial prison detention: a case study from Geneva, Switzerland.
    Favrod-Coune T; Baroudi M; Casillas A; Rieder JP; Gétaz L; Barro J; Gaspoz JM; Broers B; Wolff H
    Swiss Med Wkly; 2013; 143():w13898. PubMed ID: 24186493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safe implementation of a prison-based methadone maintenance programme: 7 year time-series analysis of primary care prescribing data.
    Wright NM; French C; Allgar V
    BMC Fam Pract; 2014 Apr; 15():64. PubMed ID: 24712316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effectiveness of opioid maintenance treatment in prison settings: a systematic review.
    Hedrich D; Alves P; Farrell M; Stöver H; Møller L; Mayet S
    Addiction; 2012 Mar; 107(3):501-17. PubMed ID: 21955033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration.
    Larney S; Toson B; Burns L; Dolan K
    Addiction; 2012 Feb; 107(2):372-80. PubMed ID: 21851442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative prices of diverted buprenorphine/naloxone and buprenorphine in a UK prison setting: a cross-sectional survey of drug using prisoners.
    Wright NM; Mohammed Z; Hughes GJ
    Drug Alcohol Depend; 2014 Nov; 144():254-8. PubMed ID: 25305714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuity of opioid substitution treatment between prison and community in Southeast Asia: A scoping review.
    Loh DA; Plugge E; Van Hout MC
    Int J Drug Policy; 2023 Feb; 112():103957. PubMed ID: 36693296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.